In Vitro and In Vivo Study of Novel PSMA-Targeted Radioligands: Enhancing Tumor Uptake and Therapeutic Efficacy through Zwitterionization and Albumin-Binding Strategies
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Yang Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Jiangyang District, Luzhou 646000, Sichuan, China. Hauptthemen laut MEDLINE: Glutamate Carboxypeptidase II, Radiopharmaceuticals, Antigens, Surface, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Southwest Medical University, National Natural Science Foundation of China, Luzhou-Southwest Medical University Cooperative Application Foundation.
Abstract (Originalsprache)
Prostate-specific membrane antigen (PSMA) targeted radioligand therapy (TRT) for metastatic castration-resistant prostate cancer has demonstrated significant potential. This study aimed to develop an optimal radiotherapeutic agent suitable for high-level PSMA expression by optimizing the ligand structure with albumin-binding zwitterionic strategies to increase tumor uptake and retention time and to explore the effects of these strategies on the in vitro and in vivo properties of PSMA inhibitors. All precursors were synthesized based on PSMA-targeting agent Flu-1. The radioligands were investigated for their physicochemical properties, imaging, and biodistribution by means of gallium and lutetium labeling to evaluate their pharmacokinetic properties, as well as their affinity and specificity for PSMA. The therapeutic effect of radioligands was systematically evaluated in [177Lu]Lu-Flu-1, [177Lu]Lu-BWD, [177Lu]Lu-P4-BWD, and [177Lu]Lu-P4-PND. All PSMA ligands were of chemical purity >95%. The final radiochemical purity of the radioligands was achieved up to 99%. The cell-based and imaging study results showed that BWD had a high affinity for PSMA (IC50 = 35.86 ± 0.56) and was significantly superior to the other radioligands in terms of tumor uptake and retention. The biodistribution study further confirmed that the tumor uptake of [177Lu]Lu-BWD (64.28 ± 12.46%ID/g) was significantly higher than that of other [177Lu]Lu-radioligands at 4 h postinjection, including [177Lu]Lu-PSMA-617 (47.64 ± 11.39%ID/g). The TRT results showed that a single injection of 7.4 MBq of [177Lu]Lu-BWD significantly inhibited the growth of PC3-PIP tumors, and it was superior to that of [177Lu]Lu-PSMA-617 under the same conditions. [177Lu]Lu-BWD with greatly enhanced tumor uptake and retention demonstrated remarkable therapeutic efficacy using significantly lower dosages for clinical translation to treat PCa with high level of PSMA expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Jiangyang District, Luzhou 646000, Sichuan, China.
- Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Jiangyang District, Luzhou 646000, Sichuan, China.
- Institute of Nuclear Medicine, Southwest Medical University, Jiangyang District, Luzhou 646000, Sichuan, China.
- Department of Pharmaceutics, School of Pharmacy, Southwest Medical University, Jiangyang District, Luzhou 646000, Sichuan, China.
- Faculty of Nursing, University of Windsor, Windsor N9B 3P4, Ontario, Canada.
- Department of Nuclear Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, Sichuan, China.
ORCID-Profile: Li Wang, Yue Chen, Nan Liu, Zhijun Zhou
Förderung
- Southwest Medical University
- National Natural Science Foundation of China
- Luzhou-Southwest Medical University Cooperative Application Foundation
Zitieren
APA
Liu, Y., Li, H., Zhou, H., Yuan, H., Zhao, Y., Yang, Z., Tang, S., Wu, T., Wang, L., Huang, Z., Chen, Y., Liu, N., & Zhou, Z. (2025). In Vitro and In Vivo Study of Novel PSMA-Targeted Radioligands: Enhancing Tumor Uptake and Therapeutic Efficacy through Zwitterionization and Albumin-Binding Strategies. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00214
Vancouver
Liu Y, Li H, Zhou H, Yuan H, Zhao Y, Yang Z, et al. In Vitro and In Vivo Study of Novel PSMA-Targeted Radioligands: Enhancing Tumor Uptake and Therapeutic Efficacy through Zwitterionization and Albumin-Binding Strategies. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00214
BibTeX
@article{Liu2025,
author = {Liu, Yang and Li, Haiyang and Zhou, Han and Yuan, Hongmei and Zhao, Yan and Yang, Zhicong and Tang, Sufan and Wu, Tongtong and Wang, Li and Huang, Zhanwen and Chen, Yue and Liu, Nan and Zhou, Zhijun},
title = {In Vitro and In Vivo Study of Novel PSMA-Targeted Radioligands: Enhancing Tumor Uptake and Therapeutic Efficacy through Zwitterionization and Albumin-Binding Strategies},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00214}
}
EUVIMED